A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
← catalyst calendarNCT06972446 · readout ≤ 193 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
180estimated
Sites
104
Countries
Canada, Czechia, Germany +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-20 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rheumatoid Arthritis
Interventions
- Drug: Lutikizumab
- Drug: Placebo
- Drug: Ravagalimab
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response
measured At Week 12
Number of Participants with Adverse Events (AEs)
measured Up to Approximately Week 22
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed